Antiangiogenic therapy in oncology: current status and future directions

GC Jayson, R Kerbel, LM Ellis, AL Harris - The Lancet, 2016 - thelancet.com
Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …

Inflammatory breast cancer biology: the tumour microenvironment is key

B Lim, WA Woodward, X Wang, JM Reuben… - Nature Reviews …, 2018 - nature.com
Inflammatory breast cancer (IBC) is a rare and aggressive disease that accounts for~ 2–4%
of all breast cancers. However, despite its low incidence rate, IBC is responsible for 7–10 …

VEGF targets the tumour cell

HL Goel, AM Mercurio - Nature Reviews Cancer, 2013 - nature.com
The function of vascular endothelial growth factor (VEGF) in cancer is not limited to
angiogenesis and vascular permeability. VEGF-mediated signalling occurs in tumour cells …

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

NS Vasudev, AR Reynolds - Angiogenesis, 2014 - Springer
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions

JW Bai, SQ Qiu, GJ Zhang - Signal Transduction and Targeted Therapy, 2023 - nature.com
Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy

X Song, C Liu, N Wang, H Huang, S He, C Gong… - Advanced drug delivery …, 2021 - Elsevier
The clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-
associated protein (Cas) systems are efficient and versatile gene editing tools, which offer …

Models and methods for analyzing DCE‐MRI: A review

F Khalifa, A Soliman, A El‐Baz… - Medical …, 2014 - Wiley Online Library
Purpose: To present a review of most commonly used techniques to analyze dynamic
contrast‐enhanced magnetic resonance imaging (DCE‐MRI), discusses their strengths and …

VEGF-targeted therapy: mechanisms of anti-tumour activity

LM Ellis, DJ Hicklin - Nature reviews cancer, 2008 - nature.com
Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as
single agents or in combination with chemotherapy, have been shown to benefit patients …

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

JJ Vredenburgh, A Desjardins, JE Herndon… - Journal of clinical …, 2007 - ascopubs.org
Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a …

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

G Niu, X Chen - Current drug targets, 2010 - ingentaconnect.com
New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and
metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway …